The protection effect reaches 67%. Kexing's new crown vaccine 10 million people have real-world research and development...

A few days ago, the Chilean Ministry of Health announced the real-world data of the inactivated vaccine CoronaVac developed by Beijing Sinovac Biotechnology Co.

Kerlaifu is an inactivated COVID-19 vaccine jointly developed by Kexing.

▲The situation of new crown vaccination in Chile (picture source: reference [2])

An analysis of real-world COVID-19 infection data from February 2 to April 1 this year shows that after two doses of Kellyford vaccination are completed 28 days apart, the effectiveness of the vaccine to prevent symptomatic COVID-19 reaches 67% , The effectiveness of preventing hospitalization reached 85%, the effectiveness of preventing entry into the intensive care unit (ICU) was 89%, and the effectiveness of preventing death was 80%.

▲Summary of the effectiveness of Kerlaifu in preventing COVD-19 (picture source: reference [2])

In addition, this study also demonstrates the importance of complete two-dose vaccination.

They found that in terms of preventing symptomatic COVID-19, the protective effect of Kellyford in some vaccinated populations was only 16.

Dr.

Reference materials:

[1] China's Sinovac COVID-19 vaccine 67% effective in preventing symptomatic infection-Chile govt report.

▽ attention [drug Mingkang Germany ] micro-channel public number